Conference on 3rd Pre-filled Syringes
|Event Date/Time: Oct 25, 2010||End Date/Time: Oct 27, 2010|
Innovative solutions for injection devices and parenteral packaging systems
25th - 27th October 2010,
BSG Conference Centre, London, UK
Todd Stephens, Global Marketing Director, Merck Serono,
Stefan SundstrÃ¶m, Director, Sterile Aseptic Manufacturing, Engineering and Maintenance, Technical Lead Sterile Process Systems, AstraZeneca,
Ian Thompson, Director of Business Development, Ypsomed,
Klaus Ullherr, Product Manager, Packaging Technology, Robert Bosch Packaging,
Jim Spolyar, Sales and Technical Director, Skan US,
Gabriele Peron, Marketing Manager, Stevanato Group - Glass Division,
Thomas Zelmer, Director, Groninger,
Sterling Kline, Director of Project Development, Integrated Project Services,
Shawn Kinney, Chief Executive Officer, Hyaluron
Elliot Lawrence, Associate Director of Regulatory Affairs, ERA Consulting,
Daniel Wheeler, Lecturer in Anaesthesia, University of Cambridge,
Andrew Longworth, General Manager, KÃ–RBER MEDIPAK UK & RoI.
With more injectable biological drugs in use than ever, the pre-filled syringes market will sustain its inexorable growth, with total revenues of $6bn by 20251.
Whether your interests lie in drug formulation, sterile manufacturing or strategic partnering,
attending this conference will enable you to:
â€¢ Overcome challenges arising from silicon-drug solution interaction
â€¢ Troubleshoot heavy-metal induced drug precipitation and microbiological contamination
â€¢ Improve dosing accuracy and enhance patient compliance with next-generation electronic devices
â€¢ Learn about novel pre-fi lled syringes for biotech products and auto injector devices
â€¢ Understand pre-fi lled syringe processing with RABS, isolators, E-beam and alternatives
â€¢ Examine factors and recent developments in processing syringe nests
â€¢ Analyse new developments in COC, COP, glass, and elastometric components
â€¢ Offset the impact of extractables and leachables on product performance
â€¢ Assess the impact of new post-market surveillance regulations on pre-filled medical devices
â€¢ Develop new strategies to remain competitive
â€¢ Obtain the latest market analysis, and meet manufacturers showcasing their leading products.
Who should attend
Presidents, Chief Executives, Chief Scientific Officers, Chief Operating
Officers, Vice Presidents, Heads, Directors, Clinicians, Principal Scientists,
Managers, Project/Team Leaders in:
â€¢ Packaging and labelling
â€¢ Vaccine, antibody and protein manufacturing
â€¢ Product design
â€¢ Technical support
â€¢ Drug product process development
â€¢ Drug device process development
â€¢ Formulation sciences
â€¢ Safe medication practice
â€¢ Drug discovery & delivery
â€¢ Clinical product resourcing
â€¢ Supply outsourcing
â€¢ Contract manufacturing and management
â€¢ Process development
â€¢ Strategic alliances
â€¢ Investment and venture capital
3rd Pre-filled Syringes
Pre-Conference Interactive Workshop
Monday 25th October 2010
About the workshop:
The session will overview the legal and regulatory issues applicable to pre-filled syringes and some of the more pressing or challenges concerns regarding their sale and use. These will include:
â€¢ Product liability
â€¢ Control of supply and distribution chains (including parallel imports, pharmacovigilance and post marketing surveillance)
â€¢ A regulatory overview
About the workshop leaders:
Alex has both a science degree (human genetics) and a law degree. He qualified as a solicitor (in Australia) in 1995. Alex spent more than five years in- house, including as general counsel and company secretary of Biotech Australia.Alex advises clients in relation to the development of strategies for the protection, defence and commercialisation of intellectual property. This involves the development of strategies and the drafting of a wide array of commercial agreements from licenses to joint ventures. Alex also advises in relation to the regulation of pharmaceuticals, medical devices and advanced therapy medicinal products. Alex has a breadth of international experience structuring, negotiating and drafting commercial agreements. Both as a corporate advisor and as in house counsel.
LDD was established to focus on advising clients in the Life Sciences sector â€“ namely the pharmaceutical, medical devices, reproductive and regenerative medicine industries. Together we bring more than 25 years experience advising clients in the sector. Our particular areas of legal expertise include regulatory matters, compliance programmes, public law and judicial review, intellectual property, commercial contracts and due diligence.
Erikâ€™s practice focuses on (medical) technology, marketing, healthcare and life sciences. He has broad experience both in litigation and in transactional work in these areas, as well as in the application of anti-trust law to high technology and pharmaceutical products.
Mathias worked as a lawyer and core member of the industry group â€œHealthcare, Life Sciences and Chemicalsâ€ at the DÃ¼sseldorf office of Clifford Chance from 2004 until 2008. He advised clients from the pharmaceutical, medical device and biotechnology industry in all regulatory matters. He focused on advising clients on healthcare fraud and abuse prevention (business compliance) and the implementation of employee guidelines and processes. He does not only know the perspective of a lawyer but also obtained a comprehensive insight into the in-house perspective within two client secondments in the European legal department of an international medical device company in Switzerland and a German pharmaceutical company. He is author of a number of publications on regulatory themes relating to pharmaceuticals and medical devices as well as co-author of the â€œHandbuch des Arzneimittelrechtsâ€ (textbook on pharmaceutical law, in prep.). Furthermore, he holds lectures and speeches on current subjects from the pharmaceutical and medical device area.
Tuesday, 26th October 2010
09:00 Registration and refreshments
09:30 Opening address from the Chair
09:40 Technology advances and market trends for auto-injectors
â€¢ User benefits.
â€¢ Creating and protecting market share.
â€¢ A new generation of device and compromises in device design.
â€¢ Future opportunities.
Director of Business Development, Ypsomed,
10:20 Achieving extra high quality production of glass primary packaging: building a manufacturing concept flow based on a streamlined process
â€¢ OMPI case study / optimised process
â€¢ Defining criteria for excellence in glass containers for pharmaceutical products
â€¢ Successfully managing critical aspects (particle control, high tolerances, contact free, silicon, traceability)
Marketing Manager, Glass Division, Stevanato Group,
10:40 Opportunities and challenges for novel primary drug containers in autoinjectors
â€¢ Analysis of suitability and weaknesses of current syringe platforms for use in autoinjectors
â€¢ Opportunities and challenges for cyclic olefins in novel primary drug containers for autoinjectors
â€¢ One approach: Ovalâ€™s novel primary drug containment technology